Skip to content

iBio’s Drug Discovery Platform2 aims to increase the likelihood of success. Using artificial intelligence (AI), our platform efficiently and consistently delivers antibody candidates against difficult targets.

At the heart of the platform is our patented epitope-engineering technology, which we use to engineer mini-proteins embodying the structure of conformational epitopes, including subdominant epitopes, to discover traditionally challenging therapeutic antibodies. An epitope is the region of a target protein to which antibodies bind. The range of potential epitopes or binding sites on a target is enormous. But not all epitopes are created equally.

Traditional drug discovery has allowed the immune system to drive epitope selection and thus biasing antibody selection towards immunodominant epitopes rather than subdominant epitopes. Often, the most efficacious epitopes are not immunodominant epitopes, but rather subdominant epitopes and therefore without epitope steering the best therapeutic antibodies are missed using traditional drug discovery methods.

By deeply integrating our Epitope-Engineering technology with a proprietary human Antibody Library, our StableHu™ Antibody Optimizer, EngageTx™ for engineering bispecifics, and ShieldTx™ for antibody masking, iBio can potentially increase the probability of success for hard-to-drug targets and move them into the clinic faster.

iBio’s Platform Tackles Discovery Challenges for the Next Era of Antibodies

iBio’s Antibody Discovery Platform In Action

Epitope-Steered Antibodies for Precision Immunotherapies and Beyond

  1. Devol, Ross & Bedroussian, Armen & Yeo, Benjamin. (2022). The Global Biomedical Industry: Preserving U.S. Leadership.
  2. U.S. Patent No. 11,545,238 (issued January 3, 2023)